U.S., Aug. 8 -- ClinicalTrials.gov registry received information related to the study (NCT07109726) titled 'A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations' on July 24.
Brief Summary: This is a Phase 1/2, open-label, multicenter study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of TER-2013 in patients with advanced solid tumors harboring AKT/PI3K/PTEN pathway alterations.
Study Start Date: Aug., 2025
Study Type: INTERVENTIONAL
Condition:
Breast Cancer
Endometrial Cancer
Ovarian Cancer
Lung Squamous Cell Carcinoma
Head and Neck Squamous Cell Carcinoma
Esophageal Squamous Cell Carcinoma
Solid Tumor
Cervical Cancer
Intervention:
D...